Churg-Strauss vasculitis with brain involvement following hepatitis B vaccination.
Lorenzo Beretta,M. Caronni,M. Vanoli,Raffaella Scorza
2001-11-01
Clinical and Experimental Rheumatology
Abstract:Sirs, Active immunisation against hepatitis B is highly effective and usually well tolerated. Side effe c t s , i n cluding feve r, a rt h ra l gi a s , fatigue and injection site pain, a re often slight, while severe systemic reactions are rare. Nevertheless, various autoimmune diseases, including vasculitis, occurring after hepatitis B vaccination have been reported (1-3). Our group has previously described a patient with hepatitis B vaccination-related C h u rg S t rauss syndrome (CSS) (3). We d e s c ribe here another case of CSS with unusual involvement of the central nervous system (CNS) which developed after vaccination against hepatitis B. A 47-ye a r-old male without a history of atopy received three doses of hepatitis B vaccine from November 1994 to May 1995. Two weeks after the third injection he developed chronic rhinitis, chronic sinusitis and nasal poly p o s i s , wh i ch we re tre at e d surgically in September 1998. In the following months he experienced severe asthmatic symptoms. Within a year fever, polyarthralgias, and purpuric lesions on the legs d eve l o p e d. Lab o rat o ry inve s t i gations revealed an elevated erythrocyte sedimentation rate (ESR, 90 mm/h), e o s i n o p h i l i a (eosinophils, 5355/mm3) and a high titre of mye l o p e roxidaseanti neutrophil cy ro p l a smic antibody (MPO-ANCA). Hepatitis C serology was negative. The anti-hepatitis B surface antigen (HBs) titre was 357 mUI/ ml. Tests for rheumatoid factor, antinuclear a n t i b o dy (ANA) and antibodies towa rd extractable nuclear antigens (ENA) were all negative. His chest X-ray was normal. No biopsy was performed. A diagnosis of CSS was proposed and the patient was given 37.5 mg of prednisone daily. In March 2000, he noticed weakness and impaired sensibility in his lower right l eg. Electro myograp hy (EMG) reve a l e d neuropathy of the peroneal ner ve. The CSS diagnosis was thus confirmed according to the 1990 criteria of the American College of Rheumatology for the classification of CSS (4) and the patient was started on therapy with methotrexate (MTX, 15 mg weekly). In following months his neurological symptoms worsened and the patient experienced tingling in the upper arms, cognitive impairment with amnesia for recent events, emotional instability and nominal aphasia. Magnetic resonance imaging of the brain ( August 2000) showed multiple hy p e ri ntense T2 lesions, compatible with demyelinated areas, throughout the white matter of both the frontal lobes and of the left temporal and parietal lobes. In December 2000 the decision was made to discontinue MTX t h e rapy, to introduce cy cl o p h o s p h a m i d e (100 mg daily) and to administer pulses of intravenous immunoglobulins (500 mg/kg every 5 weeks). The patient reported feeling well and his neurological symptoms partially receded. In our patient a temporal re l at i o n s h i p between hepatitis B vaccine administration and the appearance of the initial symptoms of vasculitis was observed, since allergic rhinitis, nasal polyposis and asthma gradually developed two weeks after the third d o s e. More ove r, the ap p e a rance 4 ye a rs later of symptoms of vasculitis, is consistent with the typical course of the disease, where respiratory symptoms may precede, even by many years, the cutaneous, neurological and systemic manifestations (5). The mechanisms by wh i ch va c c i n at i o n could trigger vasculitis are still a matter of debate (1). In genetically susceptible individuals, infections may trigger the release of p ro i n fl a m m at o ry cy t o k i n e s , p riming neutrophils and endothelial cells and thus allow ANCA to activate neutrophils to release cytokine and mediators that lead to vascular injury and recruit mononuclear cells and T lymphocytes, that perpetrate and intensify the local damage (6). We can thus assume that the administration of a virus derivedprotein, such as HBs antigen, rather than a whole infective agent, may have triggered the pathogenic mechanism described above. The present case of hep atitis B va c c i n e related CSS was complicated by unusual CNS invo l vement. Indeed, Fe rro (7) has noted that CNS involvement is rare in CSS. Nevertheless,Herrolen et al. (8) described 2 patients with CNS demyelination occurring after hep atitis B vaccine administrat i o n . This suggests that such neuro l ogical involvement may be a consequence of hepatitis B vaccination, rather than a very uncommon complication of CSS.